Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expirations, FDA safety updates, and global manufacturing data make Organon & Co’s disclosures dense. Finding how a contraceptive brand’s revenue shifted, or whether a biosimilar launch triggered new litigation, means combing through hundreds of pages. If you have ever asked, “How do I read Organon & Co SEC filings explained simply?” this page is for you.
Stock Titan’s AI turns every Organon & Co annual report 10-K simplified, Organon & Co quarterly earnings report 10-Q filing, and Organon & Co 8-K material events explained into plain-English summaries. Need real-time alerts? We capture Organon & Co Form 4 insider transactions real-time the moment they hit EDGAR, spotlighting executive stock moves before market close. Our platform links each filing type to questions investors actually ask:
- 10-K / 10-Q – segment sales for women’s health, biosimilar revenue trends, and R&D pipeline costs, plus AI-driven Organon & Co earnings report filing analysis.
- 8-K – drug-approval milestones and manufacturing notices, with concise context so understanding Organon & Co SEC documents with AI takes minutes, not hours.
- Form 4 – monitor Organon & Co insider trading Form 4 transactions and flag unusual buying in advance of biosimilar launches.
- DEF 14A – review the Organon & Co proxy statement executive compensation for insight into incentive alignment.
Whether you’re tracking patent-cliff risk or confirming Organon & Co executive stock transactions Form 4, our expert analysis and AI-powered summaries let you focus on decisions, not document mining. All filings, all in one place—updated as soon as Organon presses “submit.”
Organon & Co. (OGN) filed an amended 8-K to disclose compensation terms for Carrie S. Cox, who is serving as Executive Chair on an interim basis. The Talent Committee set her base salary at $100,000 per month, effective October 26, 2025.
The amendment notes this compensation update and states no other changes to the prior report.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 35,927,524 shares of Organon & Co. common stock, representing 13.82% of the class as of the stated event date 09/30/2025. Vanguard reports 0 shares with sole voting power, 1,689,621 with shared voting power, 33,922,797 with sole dispositive power, and 2,004,727 with shared dispositive power.
The filing classifies Vanguard as an investment adviser and includes the standard certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control. Vanguard notes its clients have rights to dividends or sale proceeds related to the reported securities, with no single client interest exceeding five percent.
Organon & Co. announced the resignation of CEO Kevin Ali and his departure from the Board in connection with an Audit Committee investigation into wholesaler sales practices. He will not receive severance or equity-related retirement benefits. Joseph Morrissey, EVP and Head of Manufacturing & Supply, was named Interim CEO; his salary is set at $1 million, bonus target at 100% of salary (prorated for this year), and his annual long-term incentive target rises to $4 million next year, plus a one-time $1 million RSU grant to be issued after the release of Q3 2025 results. Carrie S. Cox was appointed Executive Chair for an interim period.
The investigation found that certain wholesalers were asked to buy greater quantities of Nexplanon during specified periods; the incremental sales were less than 1% of consolidated revenue for 2022 or 2024 and less than 2% for the relevant quarters. The company determined no restatement or revision of prior financial statements is required. However, due to one or more material weaknesses as of December 31, 2024, management’s ICFR assessment and PwC’s ICFR opinion in the 2024 Form 10‑K should no longer be relied upon. Organon expects to file a Form 10‑K/A and Form 10‑Q/As to correct prior ICFR conclusions and intends to timely file its Q3 2025 Form 10‑Q.
Organon & Co. insider filing (Form 4) reports that Juan Camilo Arjona Ferreira, Head of R&D & CMO and an officer of Organon (OGN), had 11,519 restricted stock units vest on August 11, 2025. Those vested units were recorded as acquisitions of common stock at $0 per share. The filing also shows a disposition of 4,122 shares sold at $9.22 per share on the same date.
The form reports beneficial ownership figures after the transactions: 28,899.355 shares reported after the RSU acquisition line and 24,777.355 shares reported after the sale line. The Form 4 was signed by an attorney-in-fact on August 12, 2025. The filing notes that each RSU equals one share and that a final vesting installment is scheduled for August 11, 2026.
Organon & Co. (OGN) Q2 2025 condensed summary: Revenues were $1.594 billion for the quarter and $3.107 billion for the six months, versus $1.607 billion and $3.229 billion in the prior-year periods. Net income fell to $145 million in Q2 2025 (Q2 2024: $195 million) and $232 million year-to-date (YTD 2025) versus $396 million YTD 2024. Diluted EPS was $0.56 for the quarter and $0.89 YTD versus $0.75 and $1.53 in the prior-year periods.
Key cash and balance sheet items: cash and equivalents declined to $599 million at June 30, 2025 from $675 million at Dec 31, 2024; total assets $13.5 billion; total long-term debt (net of current portion) $8.781 billion; weighted-average interest rate on borrowings 5.0% and average maturity ~5.1 years. Operating cash flow provided $295 million YTD; investing used $210 million, including Dermavant consideration.
Material corporate actions disclosed: Dermavant acquisition (aggregate consideration $581 million; contingent consideration fair value $383 million; $75 million regulatory milestone paid in Q1 2025); March 2025 U.S. rights for Tofidence from Biogen (intangible $51 million recognized; upfront paid in July 2025); July 2025 acquisition of Oss Biotech site (aggregate $25 million, $15 million paid). The Company repurchased $242 million of 5.125% 2031 notes in Q2, recording a $42 million pre-tax gain. The Company implemented restructuring reducing headcount ~6% and recorded $88 million of restructuring costs YTD. Effective tax rates increased (Q2 2025: 37.0% vs Q2 2024: 17.3%).
FAQ
What is the current stock price of ORGANON & CO (OGN)?
What is the market cap of ORGANON & CO (OGN)?
